#France #Lyon #Endometriosis #Ziwig Endotest #ENDOmiRNA

The Precision of Ziwig Endotest® Confirmed by ENDOmiRNA Study

Ziwig, a French biotech company, has recently showcased the impressive results of its Endotest® during the Congrès Pari(s) Santé Femmes 2025. This scientific dialogue highlighted the findings of the ENDOmiRNA study published in the New England Journal of Medicine (NEJM) Evidence, which emphasizes the accuracy of salivary biomarkers in diagnosing endometriosis. With a pioneering approach to women's health diagnostics, Ziwig is leading the charge with groundbreaking advancements in salivary transcriptome analysis.

The ENDOmiRNA Study

Conducted across 17 public and private centers in France, the ENDOmiRNA study included 971 patients, confirming that the Ziwig Endotest® boasts an astounding diagnostic accuracy. The sensitivity of the test stands at 97.3% and the specificity at 94.1%, setting a new standard in endometriosis evaluation. Moreover, the study underscores the consistent performance of the Endotest® across different demographics and clinical scenarios, showing no significant variation due to geographical, temporal, or individual patient factors.

This extensive trial demonstrates the potential clinical utility of the Ziwig Endotest®, especially for patients exhibiting clinical symptoms of endometriosis but lacking conclusive imaging results. The findings reveal that it could serve as a reliable diagnostic tool for those termed “discordant” patients, who experience endometriosis-like symptoms but receive inconclusive imaging tests.

Rapid Adoption and Innovation

Furthermore, Ziwig has announced the completion of the patient inclusion phase for a clinical utility study known as ENDOBEST, which involves 2,500 patients under the Forfait Innovation scheme. This initiative approves the reimbursement of Endotest®, marking a significant step towards widespread implementation in healthcare.

Patients, approximately 22,500, now have the opportunity to receive this salivary test must be performed in over 100 specialized hospitals. The test is now part of routine clinical practice, especially for women presenting symptoms of endometriosis with non-affirmative imaging assessments. Yahya El Mir, founder and president of Ziwig, expressed gratitude towards participants and collaborators whose dedication has propelled advancements in the field, stating, “Their collective contribution has facilitated notable progress.”

The Future of Women’s Health

Ziwig's focus on enhancing women’s health reflects a broader commitment to making healthcare more personalized and accessible. By integrating molecular biology, high-throughput sequencing, and artificial intelligence, Ziwig aims to address women’s health concerns and streamline diagnostic pathways. The significance of the Ziwig Endotest® is not just limited to diagnostic results; it indicates a shift in how healthcare approaches women's conditions historically fraught with misdiagnosis and underdiagnosis.

As Ziwig moves forward, they remain committed to tackling the societal and medical challenges surrounding endometriosis, aiming to improve the quality of life for countless women. Through innovation and responsive strategies, Ziwig positions itself as a leader in the fight against endometriosis, advocating for women's rights to accurate, timely, and effective healthcare solutions.

In conclusion, the findings from the ENDOmiRNA study not only affirm the reliability of Ziwig Endotest® but also illuminate a path forward in the diagnosis of endometriosis, paving the way for improved patient outcomes and a brighter future for women's healthcare.